Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. reports developments in water technology for medical and commercial markets, with emphasis on point-of-use filtration, waterborne pathogen risk reduction, and water management support. Company news commonly covers quarterly financial results, programmatic revenue trends, service offerings, customer education, and product adoption across healthcare facilities and other complex buildings.
Updates also include expansions of Nephros' water safety capabilities, regional market initiatives, and the Nephros Water Institute, an education effort focused on water quality, infection prevention, regulatory readiness, and emergency preparedness for compromised water events.
Nephros, a water technology leader, announced that CEO Andy Astor will present at the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The event will showcase discussions with C-suite executives and feature insights into Nephros' advancements in water safety, including pathogen detection and purification technologies. The conference aims to connect thousands of issuers with investors through presentations and live Q&A sessions. For more details, visit www.nephros.com.
Nephros, Inc. (Nasdaq:NEPH) reported fourth-quarter 2020 net revenue of $2.3 million, a 26% decline from the previous year's $3.2 million. The full-year revenue dropped 17%, totaling $8.6 million compared to $10.3 million in 2019. The net loss for Q4 was approximately ($759,000), marking a significant increase from a net income of $234,000 in 2019. Adjusted EBITDA shows a loss of ($466,000) for Q4, in contrast to a profit of $374,000 a year earlier. Despite challenges due to COVID-19, the company's CEO expressed optimism for a return to growth in the latter half of 2021.
Nephros, Inc. (Nasdaq: NEPH), a water technology leader, will release its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. A conference call is scheduled for the same day at 4:30 PM ET, where management will discuss the financial results and business outlook. Call-in details include a participant dial-in number and a replay option available until March 8, 2021. Nephros focuses on advancing water safety in medical and commercial sectors through innovative filtration and pathogen detection solutions.
Nephros, Inc. (Nasdaq: NEPH) has appointed Wes Lobo as Chief Marketing Officer, effective immediately. Reporting to CEO Andy Astor, Lobo will lead strategic growth through innovative marketing solutions. With over 20 years of experience in the water business, including roles at Watts Water Technologies and Xylem, he aims to enhance customer connections and expand market reach. Nephros previously grew revenues by over 50% annually before the pandemic and seeks to regain this momentum. Lobo's expertise is anticipated to accelerate the company's growth trajectory.
Nephros, Inc. (Nasdaq: NEPH) anticipates revenues of approximately $2.3 million for Q4 2020, reflecting a 9% sequential growth from Q3, but a 27% decline year-over-year. Full-year revenue is expected to be around $8.5 million, down 17% from 2019. CEO Andy Astor noted that COVID-19 significantly impacted 2020 revenues, particularly in acquiring new customers and sales in hospitality sectors. However, the company expressed optimism for recovery and growth as vaccine distribution expands. Nephros ended the year with approximately $8.3 million in cash.
Nephros Inc. (Nasdaq: NEPH) has announced the completion of the second-generation HDF Assist Module (HDF2) and plans to file a Special 510(k) with the FDA in early 2021. Despite delays, they expect to launch HDF2 post-COVID-19 vaccination rollout. Nephros also received a patent for HDF2 technology, valid until 2038, enhancing its market positioning. Additionally, they expanded the EndoPur and S100 filter capabilities for heat disinfection, potentially doubling their market reach. These advancements aim to improve water purification in dialysis and medical facilities.
Nephros (NASDAQ: NEPH) has completed its second-generation HDF Assist Module (HDF2) technology and will file a Special 510(k) with the FDA in early 2021, delaying its original timeline. The company has also been granted a patent for the HDF2 design, which will protect its technology until 2038. Additionally, Nephros has enhanced the EndoPur and S100 product lines to withstand heat disinfection, potentially doubling their market reach. Nephros anticipates that commercial launches for the HDF2 module will occur after COVID-19 vaccinations are largely completed.
Nephros, a company listed on Nasdaq under the symbol NEPH, announced its participation in upcoming investor conferences in November 2020. The Virtual Fall Investor Summit is scheduled for November 16, 2020, at 9:30 AM ET, with a webcast available. The Craig-Hallum Capital Group's 11th Annual Alpha Select Conference follows on November 17, and the Sidoti Virtual Microcap Conference will take place on November 19, at 11:30 AM ET. Nephros specializes in water purification products and pathogen detection systems for medical and commercial markets.
Nephros, Inc. (Nasdaq:NEPH) has appointed Dan D'Agostino as its Chief Financial Officer, effective November 6, 2020. The company reported a 34% quarter-over-quarter increase in net revenue for Q3 2020, totaling $2.1 million, although this reflects a 31% decline year-over-year. The net loss widened to $1.0 million from $0.7 million in the previous year. Despite the challenges of the COVID-19 pandemic, Nephros maintains strong recurring revenues and customer retention. The company aims to expand its filtration business and enhance its pathogen detection products.
Nephros, a company focused on water purification and pathogen detection, announced it will release its third quarter 2020 financial results on November 5, 2020, after market close. The company will also host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business overview. Nephros targets medical and commercial markets with ultrafilters and pathogen detection systems, crucial for infection control in healthcare settings.